Findings from a large Asian chronic hepatitis C real-life study

Journal of Viral Hepatitis

Volumn 25, Issue 12, 2018, Pages 1533-1542

  Lim, Seng Gee ^a,b   Phyo, Wah Wah ^a   Shah, Samir R ^c   Win, Khin Maung ^d   Hamid, Saeed ^e   Piratvisuth, Teerha ^f   Tan, Soek Siam ^g   Dan, Yock Young ^a,b   Lee, Yin Mei ^a,b   Ahmed, Taufique ^h   Yang, Wei Lyn ⁱ   Chen, Kok Pun ⁱ   Kamat, Mrunal ^c   Wadhawan, Manav ^j   Madan, Kaushal ^k   Mehta, Rajiv ^l   Shukla, Akash ^m   Dhore, Prashant ^m   Eapen, Chundamannil E ⁿ   Abraham, Priya ⁿ   Tyagi, Satyendra ^o   Koshy, Abraham ^p   Bwa, Aung Hlaing ^d   Jafri, Wasim ^e   Abid, Shahab ^e   Arisar, Fakhar Ali Qazi ^e   Tanwandee, Tewesak ^q   Yin, Thing Phee ^r   Tee, Hoi Poh ^s   Hj Md Said, Rosaida Binti ^t   Goh, Khean Lee ^u   Ho, Shiaw Hooi ^u   Mohamed, Rosmawati ^u   Abu Bakar, Norasiah ^v   more..

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Global Hospital Superspeciality and Transplant Center   (India)

^d Yangon GI Liver Centre   (Myanmar)

^e AGA KHAN UNIVERSITY   (Pakistan)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g Selayang Hospital   (Malaysia)

^h KHOO TECK PUAT HOSPITAL   (Singapore)

ⁱ TAN TOCK SENG HOSPITAL   (Singapore)

^j ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^k Artemis Health Institute   (India)

^l Surat Institute of Digestive Sciences (SIDS)   (India)

^m LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

ⁿ CHRISTIAN MEDICAL COLLEGE   (India)

^o Kailashi Superspeciality Hospital   (India)

^p Lakeshore Hospital   (India)

^q MAHIDOL UNIVERSITY   (Thailand)

^r Sime Darby Medical Centre Subang Jaya   (Malaysia)

^s HOSPITAL TENGKU AMPUAN AFZAN   (Malaysia)

^t Hospital Ampang   (Malaysia)

^u UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^v Hospital Raja Perempuan Zainab II   (Malaysia)

more..

Author keywords

chronic hepatitis C; cure; genotype; sustained virologic response; treatment failure; virologic failure

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; ARTICLE; CHRONIC HEPATITIS C; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ASIA; CLASSIFICATION; COMPLICATION; GENETICS; HEPACIVIRUS; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; ASIA; BENZIMIDAZOLES; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85053917606     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12989     Document Type: Article

References (15)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128.
3. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61-80.
4. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther. 2014;39(7):686-698.
5. Hlaing NKT, Mitrani RA, Aung ST, et al. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. J Viral Hepat. 2017;24:927-935.
6. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey. CMAJ Open. 2016;4(2):E132-E140.
7. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011;106:38-45.
8. Njei B. Sofosbuvir-ribavirin duo for chronic hepatitis C. Conn Med. 2014;78(6):355-356.
9. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE, the ERCHIVES study. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016;36(5):651-658.
10. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405-414.
11. Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15(3):349-359.
12. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and safety of Sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis. 2016;63(6):776-783.
13. Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017;45(5):688-700.
14. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454-1461. e1.
15. Hill A, Khwairakpam G, Wang J, et al. High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C. J Virus Erad. 2017;3(4):200-203.